

Table SI. miScript primers.

Primer name	Primer sequence	Accession no.
hsa-miR-106a-5p	AAAAGTGCTTACAGTGCAGGTAG	YP00204563
hsa-let-7d-5p	AGAGGTAGTAGGTTGCATAGTT	MS00003136
hsa-miR-93-5p	CAAAGTGCTGTTTCGTGCAGGTAG	MS00003346
hsa-miR-320a	AAAAGCTGGGTTGAGAGGGCGA	MS00014707
hsa-miR-185-5p	TGGAGAGAAAGGCAGTTCCTGA	MIMAT0000455
hsa-miR-99b-5p	CAAGCTCGTGTCTGTGGGTCCG	MS00032172
hsa-miR-122-5p	TGGAGTGTGACAATGGTGTTTG	MS00003416
hsa-miR-92a-3p	TATTGCACTTGTCCCGGCCTGT	MIMAT0000092

miR, microRNA.

Table SII. Characteristics of patients with ovarian cancer.

Clinicopathological characteristic	Ovarian cancer, n	Healthy women, n
Age, years	$\chi^2=0.532$	P=0.596
≤50	18	17
>50	12	13
Tumor stage		
T1/T2	13	-
T3/T4	17	-
TNM stage		
I	2	-
II	4	-
III-IV	24	-
Treatment		
Surgical treatment	12	-
Non-surgical treatment ^a	18	-

TNM, Tumour-Node-Metastasis. ^aAll patients have not received any form of surgery or other treatments.

Table SIII. Summary of the upregulated miRNAs in patients with ovarian cancer compared with healthy women.

miRNA name	Fold-change	P-value
hsa-miR-106a-5p	6.7766	0
hsa-miR-584-3p	2.4604	0
hsa-miR-93-5p	2.2672	0
hsa-miR-4659a-3p	2.1980	0
hsa-miR-345-5p	1.6382	0
hsa-miR-103a-3p	1.2297	0
hsa-let-7d-5p	1.1941	0
hsa-miR-378a-3p	1.1143	0
hsa-miR-320a	1.0599	0
hsa-miR-425-3p	1.0565	0
hsa-miR-196b-5p	1.0398	0
hsa-miR-20b-5p	1.3394	2.51×10^{-275}
hsa-miR-942-5p	1.6697	9.91×10^{-260}
hsa-miR-374b-5p	1.5139	2.52×10^{-154}
hsa-miR-1246	2.0259	3.85×10^{-105}
hsa-miR-624-5p	1.1539	4.23×10^{-105}
hsa-miR-30b-5p	1.1470	1.34×10^{-88}
hsa-miR-4659b-3p	1.3527	3.71×10^{-54}
hsa-miR-339-3p	1.3117	3.08×10^{-48}
hsa-miR-579-5p	1.8093	1.58×10^{-27}
hsa-miR-505-5p	1.6602	4.11×10^{-29}
hsa-miR-330-5p	1.3375	3.05×10^{-21}
hsa-miR-3944-5p	1.5382	3.57×10^{-21}
hsa-miR-532-3p	1.2697	3.89×10^{-20}
hsa-miR-99b-3p	1.9288	7.37×10^{-12}
hsa-miR-3913-5p	1.9061	3.58×10^{-11}
hsa-miR-6513-5p	1.0670	3.63×10^{-11}
hsa-miR-374a-3p	1.2292	1.82×10^{-10}
hsa-miR-1307-5p	1.5932	4.03×10^{-8}
hsa-miR-154-5p	1.0151	6.23×10^{-8}
hsa-miR-7850-5p	1.0589	2.56×10^{-7}
hsa-miR-378a-5p	1.1177	3.46×10^{-6}
hsa-miR-320c	1.2031	0.0001270
hsa-miR-320d	1.7760	0.0002510

miRNA/miR, microRNA.

Table SIV. Summary of the downregulated miRNAs in patients with ovarian cancer compared with healthy women.

miRNA name	Fold-change	P-value
hsa-miR-4732-3p	-2.70018	0
hsa-miR-128-3p	-2.49206	0
hsa-miR-423-5p	-1.74454	0
hsa-miR-139-5p	-2.48727	0
hsa-miR-342-3p	-2.32591	0
hsa-miR-99a-5p	-1.49118	0
hsa-let-7d-3p	-2.23454	0
hsa-miR-150-5p	-2.05132	0
hsa-miR-92a-3p	-1.82245	0
hsa-miR-744-5p	-1.80408	2.5109E-275
hsa-miR-92b-3p	-1.74766	9.9114E-260
hsa-miR-122-5p	-2.48727	2.5164E-154
hsa-miR-99b-5p	-1.71621	3.8493E-105
hsa-miR-185-5p	-1.69877	4.2341E-105
hsa-miR-5010-5p	-1.56332	1.33894E-88
hsa-miR-323b-3p	-2.31042	3.70692E-54
hsa-miR-323a-5p	-1.38074	3.07954E-48
hsa-miR-139-3p	-1.28869	1.57753E-27
hsa-miR-204-5p	-1.28075	4.53442E-22
hsa-miR-509-3p	-1.15178	5.0447E-022
hsa-miR-4446-3p	-1.12531	3.04804E-21
hsa-miR-30a-5p	-1.11314	3.56974E-20
hsa-miR-4433b-3p	-3.97142	7.37085E-12
hsa-miR-4467	-3.95111	3.57668E-11
hsa-miR-95-3p	-3.06686	3.62744E-11
hsa-miR-224-5p	-3.05326	1.82144E-10
hsa-miR-497-5p	-2.92548	4.03498E-08
hsa-miR-328-3p	-2.89608	6.23481E-08
hsa-miR-409-3p	-2.89575	2.55639E-07
hsa-let-7e-3p	-2.86462	3.45669E-06
hsa-miR-125a-5p	-2.83454	0.000127243

miRNA/mir, microRNA.